1. FDA Approves Erbitux for Colorectal Cancer;Food and Drug Administration,2004
2. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC);Cunningham;Proc Am Soc Clin Oncol,2003
3. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR);Saltz;Proc Am Soc Clin Oncol,2001
4. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR);Saltz;Proc Am Soc Clin Oncol,2002